117results about How to "Promote endothelialization" patented technology

The present invention is directed to an intravascular treatment for intracranial aneurysms. The invention consists of a patch stent and, also, a patch stent delivery system allowing one to rotate the stent to align the patch with the neck of the aneurysm. A self-expanding nitinol framework holds the patch in place, a radiopaque agent allows the patch location to be visualized and a pusher tube that is mechanically locked into the unexpanded stent is used to push the stent out of the catheter with rotational and longitudinal control necessary to align the patch with the aneurysm. A self-expanding framework is used to support a patch at the neck of the aneurysm. The patch is designed to reduce the blood circulation in the aneurysm and the stagnant blood will clot or thrombus. The thrombus will stop any current blood leakage into the brain and will dramatically reduce the possibility of future leaks or potentially deadly ruptures. Over time the thrombus will be absorbed and the volume of the aneurysm will shrink reducing pressure on surrounding tissue.

Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.

A method for the provision of a coating on an implantable medical device results in a medical device having a bio-absorbable coating. The coating includes a bio-absorbable carrier component. In addition to the bio-absorbable carrier component, a dissolved therapeutic agent component can also be provided. The coated medical device is implantable in a patient to effect controlled delivery of the coating, including the dissolved therapeutic agent, to the patient.

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

A stent is provided in combination with a growth factor, specifically pleiotrophin or an analog or derivative thereof, which promotes endothelialization of the stent and re-endothelialization of the stented region of an injured site in a body lumen. In particular applications, the stent is an endolumenal stent and the growth factor promotes healing via endothelialization and substantially prevents restenosis. The growth factor is delivered from the stent formulated as a protein or peptide, or as a gene transfer vector. Methods for the treatment of vascular injury using pleiotrophin are also disclosed.

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

An implant can include a frame and a mesh component coupled to the frame. The mesh component can define a first porosity, and the frame can define a frame porosity. The combined porosity of the mesh component and the frame can restrict blood flow into the implant.

Stent, as well as a method and device for fabricating the stent, wherein the stent has a tubular lattice structure comprising individual struts and at least one strut of which at least one longitudinal section runs with at least one directional component in the radial circumferential direction of the stent, wherein the surface of the longitudinal section facing the outside of the stent is curved only about the longitudinal axis of the stent. According to the invention, the surface of longitudinal section of the strut, which surface faces the inside of the stent, has such a curvature that the strut cross section is fluidically optimized.

An endoluminal stent composed of a plurality of first structural elements arrayed to form the circumference of the stent and extending along the longitudinal axis of the stent, and a plurality of second structural elements that interconnect adjacent pairs of first structural elements. The plurality of first structural elements have either a linear shape or a generally sinusoidal configuration with either a regular or irregular periodicity or regions of regular and regions of irregular periodicity between the peaks and troughs of the pattern, with the peaks and troughs projecting from the first structural elements in the circumferential axis. The plurality of second structural elements are generally linear or sinusoidal-shaped members which interconnect an apex of a peak of one of the plurality of first structural elements with an apex of a valley of a second and adjacent one of the plurality of first structural elements. Each of the plurality of second structural elements are generally oriented parallel to the circumferential axis of the stent.

Implantable materials having engineered surfaces and method of making same comprising geometric features on at least one surface of the material having at least one of chemical, physiochemical and electrochemical activity different than regions of the at least one surface without the features.

The present invention relates to methods for treating or preventing cardiac conditions in a subject comprising administering to the subject two or more isoforms of hepatocyte growth factor (HGF). The present invention further relates to methods for promoting endothelial cell growth in a blood vessel comprising administering to the blood vessel two or more isoforms of hepatocyte growth factor (HGF). In one embodiment the two or more isoforms of HGF are administered as one or more polynucleotides encoding the isoforms.

The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same.

A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are also contemplated, for use to treat restenosis.

A vascular stent and a method for manufacturing same. The vascular stent has a mesh-shaped tubular structure. The mesh-shaped tubular structure is formed by braiding a metal wire and a biodegradable wire. The vascular stent has the following advantages: First, the stent has a thinner wall, facilitating implantation of the vascular stent into a narrower blood vessel and reducing the risk of restenosis after the stent is implanted in a small blood vessel. Secondly, the rejection caused by the presence of foreign bodies in the human body is reduced, and endothelialization of tissues is promoted. Thirdly, the vascular stent is allowed to have a greater mesh density, so that hemodynamics at the lesion site in the blood vessel can be improved after the vascular stent is implanted in the human body.

The invention relates to an effectively anti-thrombotic restenosis blood vessel inner support, and comprises a blood vessel inner support body. The invention is characterized in that the surface of the support body has a surface modifying layer which has A20 or A20 and correlation factors which can capture auto-endothelial progenitor cells in vivo, the A20 is A20 eukaryotic expression carriers, viral vectors, or A20 protein, and the correlation factors which can capture auto-endothelial progenitor cells in vivo are selected from esoderma growth factor II type receptor KDR antibodies, CD34 antibodies, or CD133 antibodies. The invention further relates to the process for preparing the support, the support can in vivo induce the endothelial progenitor cells and endothelial cells in the circulating blood to plant, and inhibit smooth muscle cells from breeding, and the performances of antithrombotic formation and anti-vessel restenosis are provided. The invention is used in the support plasty after the blood vessel is clinically provided with restenosis.